New Studies Highlight Activity of XERAVA Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, announced the presentation of new data on XERAVA (eravacycline), a novel, fully synthetic fluorocycline approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults, and TP-6076, a clinical-stage candidate targeting multidrug-resistant (MDR) infections, at the American Society for Microbiology (ASM) Microbe 2019 Annual Meeting held June 20-24 in San Francisco.

“The data presented at ASM Microbe underscore the broad potential of XERAVA as a potent antibiotic against gram-negative and gram-positive clinical isolates, including MDR pathogens,” said Larry Edwards, current Chief Operating Officer of Tetraphase and recently named President and Chief Executive Officer, effective August 1, 2019. “As we now focus our efforts squarely on the commercial success of XERAVA in complicated intra-abdominal infections, we continue to be encouraged by studies that highlight its validity as a new treatment option for serious, life-threatening infections. Additionally, as recently announced, we are looking to outlicense our early-stage pipeline, and we believe that the pharmacokinetic and efficacy data of TP-6076 strengthens this asset as an attractive outlicensing candidate.”

Studies Continue to Demonstrate the Potent In Vitro Activity of Eravacycline Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens

Carbapenem resistance is emerging in E. coli, including its MDR lineage. New agents, including XERAVA, have distinctive mechanisms that inhibit or kill many carbapenem-resistant organisms. Accordingly, Johnson et al. tested these antibiotics against clinical E. coli isolates, including those that are carbapenem resistant, from surveillance systems encompassing multiple sites across the U.S. The minimum inhibitory concentrations (MIC) of 179 U.S. clinical E. coli isolates, which were non-susceptible to one or more carbapenems, were determined with cefiderocol, ceftazidime-avibactam and XERAVA; three carbapenems (meropenem, imipenem, ertapenem); and eight non-carbapenem comparators. Using FDA/Clinical and Laboratory Standards Institute (CLSI) breakpoint interpretations, the percent susceptible isolates was higher for cefiderocol (96%), ceftazidime-avibactam (92%), and XERAVA (97%) than for any carbapenem (meropenem, 75%; imipenem, 46%; ertapenem, 3%) and for all other comparators except tigecycline (98%) and colistin (99%). These data demonstrated that cefiderocol, ceftazidime-avibactam and XERAVA were highly active overall among the carbapenem-resistant E. coli clinical isolates, notwithstanding variation by phylogroup, clonal group, New Delhi metallo-beta-lactamase genotype and geographical region. Given these results, XERAVA may be a promising new treatment option for infections caused by carbapenem-resistant, multidrug-resistant E. coli.